Deals & Corporate Governance

  • July 02, 2026

    The Firms That Won Big At The Supreme Court

    This U.S. Supreme Court term featured high-stakes oral arguments on issues including presidential power, immigration and voting regulations. Here's a look at the law firms that argued the most cases and how they fared.

  • July 02, 2026

    The Sharpest Dissents From The Supreme Court Term

    The sharpest dissents this term often involved the president, and pitted conservative and liberal justices against each other on core constitutional issues and questions about the limits to executive power, with nearly a quarter of cases being decided squarely along ideological lines.

  • July 02, 2026

    The Year Donald Trump Won Big At The High Court

    The Supreme Court's conservative supermajority and President Donald Trump largely aligned this year on issues of executive power, resulting in a series of decisions that significantly expanded presidential authority.

  • July 02, 2026

    Chubb, Lloyd's Units Seek Further Win Against Opioid Suits

    Chubb, Liberty Mutual and Lloyd's of London units and other insurers urged a Pennsylvania federal court to find that they don't owe any additional coverage to bankrupt pharmaceutical company Endo International for the remainder of third-party payor opioid lawsuits filed against Endo during its 2017-2018 policy period.

  • July 02, 2026

    United Therapeutics Buys Thymmune For Up To $300M

    Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million.

  • July 02, 2026

    Breaking Down The Vote: The High Court Term In Review

    The U.S. Supreme Court's stark ideological divisions were on full display this term, particularly as it issued long-awaited rulings in the last few days of June. Here, Law360 dives into the numbers behind this court term.

  • July 01, 2026

    Ipsen Buying Memo Therapeutics For Up To $800M

    French drugmaker Ipsen said Wednesday it has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a deal that could be worth more than €700 million ($796.6 million), expanding its pipeline of treatments for rare diseases.

  • June 30, 2026

    Healthcare Deals This Week: Merck, Novartis And More

    It was deal after deal this past week, as Big Pharma continued to scoop up companies.

  • June 30, 2026

    Health Attys Talk Cooperation In Gov't Fraud Investigations

    For attorneys defending healthcare clients hit with grand jury subpoenas and other enforcement actions investigating potential cases of fraud, cooperation with federal prosecutors is key.

  • June 30, 2026

    Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims

    A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors before the IPO that its drug-development costs were high and rising, and therefore did not have to provide a quarter-by-quarter spending breakdown.

  • June 30, 2026

    UCHealth Workers Fight Bid To Toss Wage Suit

    Two former hospital workers urged a Colorado federal court to keep alive their proposed class and collective action alleging University of Colorado Health shorted hourly employees through a time-rounding policy and denied them required meal and rest breaks, saying their claims are sufficiently detailed to proceed.

  • June 29, 2026

    Insulin Makers Can't Nix 340B Antitrust Claims On Remand

    A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most of their state-law antitrust claims to survive but dismissing their unjust enrichment claims.

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 26, 2026

    Wash. Healthcare Firm's Ex-CEO Admits To Embezzling $24M

    A former chief executive officer of Washington-based Community Clinic Network has pled guilty to wire fraud in Washington federal court, admitting he drained almost $24.4 million from the healthcare company's coffers, most of which he lost in a series of poor investment decisions.

  • June 26, 2026

    Taxation With Representation: Sidley, Paul Weiss, Kirkland

    In this week's Taxation With Representation, Germany's Merck KGaA acquires life sciences tools supplier Bio-Techne Corp., drugmaker AbbVie buys clinical-stage biotechnology company Apogee Therapeutics, and building materials supplier CRH acquires infrastructure products maker Arcosa Inc.

  • June 25, 2026

    4th Circ. Says Supply Co.'s Foreign Member Kills Diversity

    The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.  

  • June 24, 2026

    11th Circ. Urged To Toss Convictions In $1.4B Hospital Fraud

    Two brothers convicted in a $1.4 billion scheme to bill insurers inflated rates for drug tests told the Eleventh Circuit on Wednesday that there was insufficient evidence to support their convictions and that they should have been allowed an evidentiary hearing after potential juror misconduct emerged following the trial.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    Sorrento RICO Case Naming Jackson Walker Gets Axed

    A Texas bankruptcy judge blocked a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection in an "ethically compromised" bankruptcy court, ruling the suit's claims are barred by Sorrento's bankruptcy plan.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 16, 2026

    Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics

    Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

  • June 12, 2026

    Taxation With Representation: Gibson Dunn, Davis Polk, S&C

    In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.

  • June 11, 2026

    Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger

    Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.

  • June 10, 2026

    Judge Won't Certify Class Of Health Workers In No-Poach Suit

    An Illinois federal judge on Wednesday refused to certify a class of former healthcare employees claiming that their wages were suppressed by alleged no-poach agreements among DaVita, UnitedHealth Group's Surgical Care Affiliates and Tenet Healthcare Corp. unit United Surgical Partners International, ruling that the proposed class is too diverse.

Expert Analysis

  • How Maine's Expanded Health Deal Reviews Complicate M&A

    Author Photo

    A pair of recently approved Maine competition laws establish notice and approval requirements for certain healthcare transactions and expand state antitrust oversight, creating new hurdles for dealmakers as states take a more aggressive role in policing healthcare consolidation, especially involving private equity, say attorneys at McDermott.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • 8 Ways 2026's Market Divide Is Rewriting Real Estate Risk

    Author Photo

    As construction activity increasingly concentrates in data centers, healthcare and other resilient sectors, real estate developers and their counsel in the second half of 2026 should consider earlier risk allocation and more protective contract terms, and expect greater pressure on labor, pricing and infrastructure, say attorneys at Cozen O'Connor.

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Risk Reduction Lessons For PE Firms From PowerSchool Suit

    Author Photo

    A California federal court's recent orders allowing claims against Bain Capital to proceed based on a data breach at its subsidiary PowerSchool indicate that private equity firms need to strategically approach acquisition activities to avoid cybersecurity risks, say attorneys at Womble Bond.

  • PowerSchool Data Breach Ruling Underscores PE Liability

    Author Photo

    The recent California federal court decision in PowerSchool, where Bain Capital was unable to dismiss claims relating to a data breach based in part on Bain's preinvestment activities, is an important addition to the line of cases addressing investor liability for acts of a portfolio company, says Mark Kelley at MoloLamken.

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Bid Protest Spotlight: Evidence, Tailored Talks, Materiality

    Author Photo

    In this month's bid protest roundup, Brian Doll at MoFo delves into three recent decisions from the Government Accountability Office about the evidentiary standards necessary to sustain a protest, discussions tailored to individual proposals, and misrepresentation claims involving factors irrelevant to the agency's decision.

  • Senior Housing Demands A Distinct Dealmaking Playbook

    Author Photo

    An aging population and evolving state regulations underscore a critical reality that senior housing assets can undergo operational or compliance shifts during dealmaking, highlighting the need for unique contractual safeguards like expanded disclosures, anchored notice obligations, and targeted closing conditions and remedies, say attorneys at Goodwin.

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.